<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Maat Pharma — News on 6ix</title>
    <link>https://6ix.com/company/maat-pharma</link>
    <description>Latest news and press releases for Maat Pharma on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 20 May 2026 18:46:04 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/maat-pharma" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d533a9beedb30cb6f6e21d.webp</url>
      <title>Maat Pharma</title>
      <link>https://6ix.com/company/maat-pharma</link>
    </image>
    <item>
      <title>MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-provides-an-update-on-the-application-for-marketing-authorization-of-maat013-xervytegr-in-the-treatment-of-acute-graft-versus-host-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-provides-an-update-on-the-application-for-marketing-authorization-of-maat013-xervytegr-in-the-treatment-of-acute-graft-versus-host-disease</guid>
      <pubDate>Wed, 20 May 2026 18:46:04 GMT</pubDate>
      <description>MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host</description>
    </item>
    <item>
      <title>MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-announces-publication-of-retrospective-data-in-third-line-acute-gvhd-from-the-chronos-study-in-bone-marrow-transplantation-journal-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-announces-publication-of-retrospective-data-in-third-line-acute-gvhd-from-the-chronos-study-in-bone-marrow-transplantation-journal-1</guid>
      <pubDate>Wed, 01 Apr 2026 05:30:00 GMT</pubDate>
      <description>LYON, France, April 01, 2026--MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal.</description>
    </item>
    <item>
      <title>MaaT Pharma Announces 2025 Annual Results and Provides Business Updates</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-announces-2025-annual-results-and-provides-business-updates-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-announces-2025-annual-results-and-provides-business-updates-1</guid>
      <pubDate>Tue, 31 Mar 2026 05:30:00 GMT</pubDate>
      <description>LYON, France, March 31, 2026--MaaT Pharma Announces 2025 Annual Results and Provides Business Updates</description>
    </item>
    <item>
      <title>MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-presents-the-ares-phase-3-pivotal-trial-final-data-during-the-presidential-plenary-session-at-the-52nd-annual-meeting-of-the-european-society-for-bone-and-marrow-transplantation-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-presents-the-ares-phase-3-pivotal-trial-final-data-during-the-presidential-plenary-session-at-the-52nd-annual-meeting-of-the-european-society-for-bone-and-marrow-transplantation-1</guid>
      <pubDate>Mon, 23 Mar 2026 17:00:00 GMT</pubDate>
      <description>LYON, France, March 23, 2026--MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the EBMT</description>
    </item>
    <item>
      <title>MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-to-present-four-abstracts-at-the-52nd-european-bone-marrow-transplantation-annual-meeting-and-to-highlight-clinigen-hosted-industry-symposium-on-acute-gvhd-management-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-to-present-four-abstracts-at-the-52nd-european-bone-marrow-transplantation-annual-meeting-and-to-highlight-clinigen-hosted-industry-symposium-on-acute-gvhd-management-1</guid>
      <pubDate>Mon, 09 Mar 2026 17:00:00 GMT</pubDate>
      <description>LYON, France, March 09, 2026--MaaT Pharma to Present Four Abstracts at the 52nd EBMT Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management</description>
    </item>
    <item>
      <title>MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-monthly-information-regarding-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-monthly-information-regarding-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital-1</guid>
      <pubDate>Tue, 03 Feb 2026 17:00:00 GMT</pubDate>
      <description>LYON, France, February 03, 2026--Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital</description>
    </item>
    <item>
      <title>MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-announces-first-patient-randomized-in-immunolife-phase-2-study-sponsored-by-gustave-roussy-to-explore-the-role-of-the-gut-microbiome-to-overcome-ici-resistance-in-advanced-nsclc-patients-with-antibiotic-induced-dysbiosis-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-announces-first-patient-randomized-in-immunolife-phase-2-study-sponsored-by-gustave-roussy-to-explore-the-role-of-the-gut-microbiome-to-overcome-ici-resistance-in-advanced-nsclc-patients-with-antibiotic-induced-dysbiosis-1</guid>
      <pubDate>Tue, 20 Jan 2026 17:30:00 GMT</pubDate>
      <description>LYON, France, January 20, 2026--MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC patients.</description>
    </item>
    <item>
      <title>MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-presents-pivotal-ares-phase-3-results-for-maat013-xervytegr-in-acute-gvhd-at-ash-2025-annual-congress-and-announces-54percent-1-year-overall-survival-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-presents-pivotal-ares-phase-3-results-for-maat013-xervytegr-in-acute-gvhd-at-ash-2025-annual-congress-and-announces-54percent-1-year-overall-survival-1</guid>
      <pubDate>Mon, 08 Dec 2025 17:00:00 GMT</pubDate>
      <description>LYON, France, December 08, 2025--MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival.</description>
    </item>
    <item>
      <title>MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-presents-updated-preclinical-data-at-sitc-annual-meeting-demonstrating-immune-activation-and-anti-tumor-activity-of-maat034-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-presents-updated-preclinical-data-at-sitc-annual-meeting-demonstrating-immune-activation-and-anti-tumor-activity-of-maat034-1</guid>
      <pubDate>Wed, 05 Nov 2025 06:30:00 GMT</pubDate>
      <description>LYON, France, November 05, 2025--MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034.</description>
    </item>
    <item>
      <title>MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-reports-financial-results-for-the-third-quarter-2025-and-provides-financing-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-reports-financial-results-for-the-third-quarter-2025-and-provides-financing-update-1</guid>
      <pubDate>Tue, 04 Nov 2025 06:30:00 GMT</pubDate>
      <description>LYON, France, November 04, 2025--MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update</description>
    </item>
    <item>
      <title>MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-announces-positive-phase-3-results-evaluating-xervytegr-maat013-in-acute-graft-versus-host-disease-selected-for-oral-presentation-at-ash-congress-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-announces-positive-phase-3-results-evaluating-xervytegr-maat013-in-acute-graft-versus-host-disease-selected-for-oral-presentation-at-ash-congress-2025-1</guid>
      <pubDate>Mon, 03 Nov 2025 17:00:00 GMT</pubDate>
      <description>LYON, France, November 03, 2025--MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in aGvHD Selected for Oral Presentation at ASH Congress 2025.</description>
    </item>
    <item>
      <title>MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-announces-positive-second-safety-interim-analysis-from-dsmb-for-phase-2b-phoebus-trial-evaluating-maat033-for-patients-receiving-allo-hsct-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-announces-positive-second-safety-interim-analysis-from-dsmb-for-phase-2b-phoebus-trial-evaluating-maat033-for-patients-receiving-allo-hsct-1</guid>
      <pubDate>Tue, 07 Oct 2025 05:30:00 GMT</pubDate>
      <description>LYON, France, October 07, 2025--MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT</description>
    </item>
    <item>
      <title>MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-publishes-its-half-year-2025-results-and-provides-a-business-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-publishes-its-half-year-2025-results-and-provides-a-business-update-1</guid>
      <pubDate>Wed, 17 Sep 2025 05:30:00 GMT</pubDate>
      <description>LYON, France, September 17, 2025--MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update.</description>
    </item>
    <item>
      <title>MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-secures-euro375-million-loan-from-european-investment-bank-eib-marking-a-new-step-in-advancing-its-clinical-program-in-hemato-oncology-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-secures-euro375-million-loan-from-european-investment-bank-eib-marking-a-new-step-in-advancing-its-clinical-program-in-hemato-oncology-1</guid>
      <pubDate>Mon, 28 Jul 2025 05:30:00 GMT</pubDate>
      <description>LYON, France, July 28, 2025--MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Oncology</description>
    </item>
    <item>
      <title>MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-half-year-report-to-the-liquidity-contract-with-kepler-cheuvreux-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-half-year-report-to-the-liquidity-contract-with-kepler-cheuvreux-1</guid>
      <pubDate>Thu, 24 Jul 2025 16:00:00 GMT</pubDate>
      <description>LYON, France, July 24, 2025--MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux</description>
    </item>
    <item>
      <title>MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-announces-exclusive-commercialization-partnership-with-clinigen-for-xervytegr-in-acute-graft-versus-host-disease-in-europe-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-announces-exclusive-commercialization-partnership-with-clinigen-for-xervytegr-in-acute-graft-versus-host-disease-in-europe-1</guid>
      <pubDate>Wed, 02 Jul 2025 16:30:00 GMT</pubDate>
      <description>LYON, France, July 02, 2025--MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe</description>
    </item>
    <item>
      <title>MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-presents-the-results-of-its-annual-ordinary-and-extraordinary-general-meeting-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-presents-the-results-of-its-annual-ordinary-and-extraordinary-general-meeting-1</guid>
      <pubDate>Tue, 24 Jun 2025 18:00:00 GMT</pubDate>
      <description>LYON, France, June 24, 2025--MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting</description>
    </item>
    <item>
      <title>MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-provides-a-business-update-and-highlights-key-milestones-expected-in-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-provides-a-business-update-and-highlights-key-milestones-expected-in-2025-1</guid>
      <pubDate>Thu, 19 Jun 2025 17:00:00 GMT</pubDate>
      <description>LYON, France, June 19, 2025--MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025</description>
    </item>
    <item>
      <title>MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-presents-updated-positive-data-in-early-access-program-for-xervytegr-at-the-eha-congress-validating-high-efficacy-observed-in-pivotal-ares-study-in-acute-graft-versus-host-disease-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-presents-updated-positive-data-in-early-access-program-for-xervytegr-at-the-eha-congress-validating-high-efficacy-observed-in-pivotal-ares-study-in-acute-graft-versus-host-disease-1</guid>
      <pubDate>Fri, 13 Jun 2025 05:30:00 GMT</pubDate>
      <description>LYON, France, June 13, 2025--MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Annual Congress.</description>
    </item>
    <item>
      <title>MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease</title>
      <link>https://6ix.com/company/maat-pharma/news/maat-pharma-advances-toward-commercialization-and-submits-marketing-authorization-application-to-the-european-medicines-agency-ema-for-xervytegr-maat013-in-acute-graft-versus-host-disease-1</link>
      <guid isPermaLink="true">https://6ix.com/company/maat-pharma/news/maat-pharma-advances-toward-commercialization-and-submits-marketing-authorization-application-to-the-european-medicines-agency-ema-for-xervytegr-maat013-in-acute-graft-versus-host-disease-1</guid>
      <pubDate>Mon, 02 Jun 2025 16:30:00 GMT</pubDate>
      <description>LYON, France, June 02, 2025--MaaT Pharma submits today a Marketing Authorization Application (MAA) to the EMA for MaaT013, under the registered brand name of Xervyteg®.</description>
    </item>
  </channel>
</rss>